19 related articles for article (PubMed ID: 37481466)
1. Insulin-like growth factor binding protein 3 promoter variant (rs2854744) is associated with nonalcoholic fatty liver disease.
Mahmoudi T; Nouri S; Zarei F; Najafabadi ZN; Sanei M; Sayedsalehi S; Rezamand G; Asadi A; Dabiri R; Nobakht H; Farahani H; Tabaeian SP; Zali MR
Arch Endocrinol Metab; 2023 Nov; 68():e230017. PubMed ID: 37948568
[TBL] [Abstract][Full Text] [Related]
2. A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease.
Mahmoudi T; Ghorbani D; Rezamand G; Dehestan N; Jeddi G; Asadi A; Nobakht H; Dabiri R; Farahani H; Tabaeian SP; Zali MR
Per Med; 2023 Mar; 20(2):157-165. PubMed ID: 37199515
[No Abstract] [Full Text] [Related]
3. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
Fujii H; Suzuki Y; Sawada K; Tatsuta M; Maeshiro T; Tobita H; Tsutsumi T; Akahane T; Hasebe C; Kawanaka M; Kessoku T; Eguchi Y; Syokita H; Nakajima A; Kamada T; Yoshiji H; Kawaguchi T; Sakugawa H; Morishita A; Masaki T; Ohmura T; Watanabe T; Kawada N; Yoda Y; Enomoto N; Ono M; Fuyama K; Okada K; Nishimoto N; Ito YM; Kamada Y; Takahashi H; Sumida Y;
Hepatol Res; 2023 Nov; 53(11):1059-1072. PubMed ID: 37537735
[TBL] [Abstract][Full Text] [Related]
5. Hepatomegaly and fatty liver disease secondary to central hypothyroidism in combination with macrosomia as initial presentation of IGSF1 deficiency syndrome.
Nikolaou M; Vasilakis IA; Marinakis NM; Tilemis FN; Zellos A; Lykopoulou E; Traeger-Synodinos J; Kanaka-Gantenbein C
Hormones (Athens); 2023 Sep; 22(3):515-520. PubMed ID: 37493943
[TBL] [Abstract][Full Text] [Related]
6. Association of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes polymorphisms with OSA and NAFLD in Asian Indians.
Bhatt SP; Guleria R
PLoS One; 2021; 16(8):e0245408. PubMed ID: 34449768
[TBL] [Abstract][Full Text] [Related]
7. Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population.
Chan SH; Chen JH; Li YH; Tsai LM
J Biomed Sci; 2012 Dec; 19(1):100. PubMed ID: 23216712
[TBL] [Abstract][Full Text] [Related]
8. The IRS2 Gly1057Asp variant is associated with human longevity.
Barbieri M; Rizzo MR; Papa M; Boccardi V; Esposito A; White MF; Paolisso G
J Gerontol A Biol Sci Med Sci; 2010 Mar; 65(3):282-6. PubMed ID: 19887537
[TBL] [Abstract][Full Text] [Related]
9. A 3'-untranslated region variant (rs2289046) of insulin receptor substrate 2 gene is associated with susceptibility to nonalcoholic fatty liver disease.
Dabiri R; Mahmoudi T; Sabzikarian M; Asadi A; Farahani H; Nobakht H; Maleki I; Mansour-Ghanaei F; Derakshshan F; Zali MR
Acta Gastroenterol Belg; 2020; 83(2):271-276. PubMed ID: 32603046
[TBL] [Abstract][Full Text] [Related]
10. Association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer in Turkish subjects.
Gorgisen G; Karatas U; Ates C; Oksuz M; Gulacar IM
Oncol Lett; 2020 Aug; 20(2):2016-2020. PubMed ID: 32724448
[TBL] [Abstract][Full Text] [Related]
11. Insulin receptor substrate 2 gene Gly1057Asp polymorphism is a risk factor for nonalcoholic fatty liver disease.
Nouri S; Mahmoudi T; Hojjati F; Najafabadi ZN; Shafiee R; Sayedsalehi S; Dehghanitafti A; Ardalani A; Kohansal K; Rezamand G; Asadi A; Nobakht H; Dabiri R; Farahani H; Tabaeian SP; Zali MR
Lab Med; 2024 Mar; 55(2):215-219. PubMed ID: 37481466
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
